4.2.2.2 Inquiries about Health Effects Submitted by CCP Manufacturers
NIOSH also received docket submissions from CCP manufacturers describing inquiries they had received about alleged adverse health effects associated with use of CCP. These inquiries are summarized in this section.
Appleton Papers, Inc. 1987. A letter from Duane Jones at Appleton Papers, Inc. (dated August 18, 1987, and submitted to the NIOSH docket) reported that from 1976 to 1986, Appleton received an average of six inquiries per month (with a range of one to nine per month) regarding skin, headache, nausea, odor, breathing, eyes, nose, mouth, and unspecified symptoms. No seasonal or other patterns were reported in the frequency of symptoms. Table 4–2 summarizes these data. Other details are contained in the NIOSH docket submission.
Moore Business Forms, Inc. 1987. An August 24, 1987, letter to Richard Lemen from Dr. Norman Macaulay of Moore Business Forms, Inc., noted that in the past 5 years (1982 to 1987), Moore had received only 23 inquiries concerning CCP, and only 6 of 7,500 customers had inquired about skin irritation that they thought was associated with CCP. Also, Moore had produced 13 billion CCP forms during the previous year.
CCP Manufacturers 1998. A letter dated October 6, 1998, was received from Robert G. Tardiff, Ph.D. (representing the CCP manufacturers in the United States) in response to a query from NIOSH. The Institute had asked whether the end users of CCP were reporting to the CCP manufacturers and sellers any health-related symptoms that might be perceived to be associated with CCP in the workplace over the last 10 years (1987–1996). Each of the five U.S. manufacturers contributed data, which were normalized to the amount of paper sold yearly. The letter stated that the figure might be overestimated, based on the following rationale: (1) customers, unsure of which manufacturer’s paper was and is being used, might have addressed the same inquiry to several different companies; (2) a customer might inquire at different levels within the manufacturing and distribution chain, with each contact being treated as a separate report; (3) a consumer might
| Item | Number | % | ||
|---|---|---|---|---|
| Focus of inquiry: | ||||
| Skin | 246 | 28.3 | ||
| Headache, nausea | 46 | 5.2 | ||
| Odor | 151 | 17.4 | ||
| Breathing | 33 | 3.3 | ||
| Eyes, nose, throat | 108 | 12.4 | ||
| Unspecified | 284 | 32.7 | ||
| Total | 868 | 99.3 | ||
